DKK1 and ovarian cancer: Our results of cisplatin sensitization from NSCLC were however validated also in ovarian cancer cells which were sensitized to cisplatin upon siRNA knockdown of DKK1. Yet we could not sensitize the acquired cisplatin-resistant subclone A2780 cis at the level of knockdown achieved in our experiments.